A. Blocking proximal renal tubular glucose reabsorption increases urinary glucose loss despite ongoing ketogenesis
Why this is correct
Sodium–glucose cotransporter 2 inhibitors block glucose reabsorption in the early proximal tubule, causing glycosuria and lowering measured plasma glucose independently of insulin secretion. During fasting, illness or perioperative stress, reduced effective insulin action and increased glucagon-to-insulin balance can permit lipolysis and substantial ketone generation even with glucose below the traditional DKA threshold. This is SGLT2 inhibitor-associated euglycemic DKA and must be recognized from ketonemia and acidosis, not dismissed because glucose is only modestly elevated.
Why each option is correct or incorrect
Correct: SGLT2 blockade increases glycosuria, masking severe insulin-deficient ketogenesis with lower plasma glucose.
SGLT2 agents do not primarily stimulate GLUT4 to completely shut off lipolysis.
SGLT2 blockade can increase rather than abolish the glucagon-to-insulin ratio and ketogenesis risk.
Compensatory renal acid handling is not sufficient to prevent severe acidosis in this syndrome.
High-yield notes
- SGLT2 inhibitors act at proximal tubular sodium–glucose cotransport.
- Euglycemic DKA can present with marked anion-gap acidosis and high ketones without marked hyperglycemia.
- Fasting, surgery, acute illness and insulin reduction can precipitate SGLT2-associated DKA.
Do not rule out DKA solely because serum glucose is below 200 mg/dL in a patient taking an SGLT2 inhibitor.
Ketones and acid-base status—not isolated glucose—are the critical diagnostic clues in euglycemic DKA.